Telix Pharmaceuticals reported US$247 million in quarterly group revenue for Q2 2026, up 21% year over year and 7% from the prior quarter, driven by growth in its Precision Medicine unit. Precision Medicine revenue reached US$202 million, a 30% rise year over year, with US dose volumes up 7% as Gozellix expands alongside the PSMA imaging portfolio. The company updated FY 2026 guidance to exceed US$1 billion in revenue and other income, supported by a US$40 million non-refundable payment from Regeneron, and lifted R&D guidance to US$230–270 million to accelerate its clinical programs. Regulatory progress included FDA alignment for the TLX591-Tx Phase 3 study to move to Part 2 in the US and a phase in Japan for Illuccix with an NDA planned, while Telix also advanced its collaboration with Regeneron and completed a refinancing of its convertible bonds. Telix announced ongoing enrollment for the BiPASS pre-biopsy study and progress in its Phase 3 registrational study in Japan, signaling potential market expansion for PSMA imaging in early prostate cancer diagnosis. The company reinforced strategic momentum across its manufacturing footprint, partnerships, and governance with new non-executive directors joining the board.